Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Testosterone and Insulin Sensitivity in IHH
NCT03118479Phase 1Terminated
- Sponsor
- Massachusetts General Hospital
- Start
- May 2010
- Primary completion
- Sep 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of testosterone in idiopathic hypogonadotropic hypogonadism (IHH) and Kallmann syndrome (KS) (2 arms), sponsored by Massachusetts General Hospital. Primary endpoints: Change in glucose tolerance at 3 months and Change in insulin sensitivity at 3 months. Started May 2010; status: terminated.
02
Drugs
testosterone
03
Conditions
idiopathic hypogonadotropic hypogonadism (IHH)Kallmann syndrome (KS)
Beyond the preview
Go deeper on NCT03118479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03118479.